GE HealthCare to present portfolio of precision care at SNMMI
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
GE HealthCare drives growth with investment in AI-enabled medical devices and tops FDA's list of AI authorizations for 4th Year with 100
Increased R&D investments to integrate AI on devices across disease states designed to boost productivity, efficiency, and diagnostic confidence for healthcare professionals, and drive the company's long-term growth Milestone advances GE HealthCare's goal of attaining more than 200 authorizations by 2028 CHICAGO, July 23, 2025--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device authorizations for the fourth year in a row with 100 listed authorizations to date in the U.S. This milestone reflects GE HealthCare's continued research and development (R&D) investment and focus on developing AI solutions to advance precision care by enhancing medical devices across the care journey. Smart devices, software, and cloud-based solutions, which are central to GE HealthCare's precision care strategy, help enhance outcomes for patients, improve the daily work of care teams, and boost healthcare professional efficiency. These AI-enabled devices help solve customer challenges and are in high demand, which contributes to orders, revenue, and growth for the company. The momentum demonstrates GE HealthCare's progress toward achieving its goal of securing more than 200 authorizations. "Our sustained leadership in AI-enabled medical devices reflects our commitment to research and development, which is powering the creation of next-generation solutions. These solutions are designed to address the toughest challenges our customers are facing including care team shortages and burnout, rising costs, and inefficient workflows," said Dr. Taha Kass-Hout, GE HealthCare's Global Chief Science and Technology Officer. "As we continue to drive the industry forward, we remain committed to doing so in a responsible way, building in our Responsible AI principles at every stage of our product development which include a focus on safety, validity, transparency, explainability, and fairness." The FDA's webpage, Artificial Intelligence-Enabled Medical Devices, provides a list of device authorizations, granted through 510(k) clearances, De Novo requests, or by premarket approval (PMA). GE HealthCare's 100 authorizations to date demonstrate innovation across imaging modalities and care pathways including oncology, cardiology, and neurology, helping to ease the burden of care and improve workflows for healthcare systems. Examples of GE HealthCare's AI solutions that are helping solve customer challenges and driving growth include: AI-based Auto Positioning uses deep learning to automatically detect anatomical landmarks, which are used to determine the patient's orientation inside computed tomography (CT) and positron emission tomography (PET)/CT devices, including Revolution Apex platform and Omni Legend. The solution helps minimize the action required by technologists into a single click operation, enabling faster patient positioning compared to traditional manual positioning operations.1 AIR™ Recon DL is a pioneering deep learning algorithm for image reconstruction that enables radiologists to achieve pin-sharp images quicker. By combining magnetic resonance imaging (MRI) with deep learning, AIR™ Recon DL reduces artifacts, enhances image clarity, and shortens scan times by up to 50%.2 It has been estimated that more than 50 million patients have been scanned since its launch in 2020.3 The LOGIQ™ Series ultrasound portfolio of systems empowers clinicians to scan, diagnose, and treat a wide range of patients and conditions. With AI-powered automation, real-time workflow enhancements, and exceptional image quality, the LOGIQ Series is designed to facilitate faster, more efficient scanning and support diagnostic precision. Intelligent anatomy recognition enables dynamic image optimization as well as repeatable and reproducible automated measurements and results – providing elevated accuracy and greater diagnostic confidence. Precision DL is deep learning-based image processing, available on the Omni Legend PET/CT system, that enhances image quality in PET/CT scans, providing clinicians with a powerful solution to aid in precise diagnoses, treatment planning, and monitoring with the image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, without compromising sensitivity, including improved contrast-to-noise ratio, contrast recovery4, and quantitative accuracy.5 Venue Family point-of-care ultrasound systems with AI-powered Caption Guidance™ software provides real-time, step-by-step guidance to help even new ultrasound users capture cardiac views and diagnostic-quality images successfully. "We're accelerating the pace of innovation to meet the urgency of today's healthcare challenges. Reaching this milestone is also an important step along our journey of evolving from an imaging company to a healthcare solutions provider, enabling us to deliver holistic and integrated solutions that meet our customers' needs today and will help enable them to stay ahead in a rapidly evolving healthcare environment," said Kass-Hout. GE HealthCare is pushing forward the boundaries of innovation by fostering new ways to use AI, cloud, and software to move the future of healthcare forward in a responsible way in devices, across the care journey, and at the hospital system level. These projects and innovations run the gamut from early R&D to commercially available solutions, often the result of working closely with leading medical institutions, universities, and technology companies to bring in the best thinking from industry, technology, and academia. Regardless of a project's maturity, GE HealthCare combines deep healthcare expertise, a commitment to responsible innovation, and pioneering spirit to help customers address pressing global challenges from aging populations, chronic disease management, remote care, and more. For more information about GE Healthcare's AI-enabled medical device and enterprise software solutions, visit About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. 1 "AI-based Auto Positioning," February 2021, 2 AIR™ Recon DL, 3 Calculated using IB data with an estimation of 20 scans per day, 5.5 days per week, from 4 weeks after delivery to April 2025. 4 Precision DL with Omni Legend 32cm data improves Contrast Recovery (CR) by 11% on average and Contrast-to-Noise Ratio (CNR) by average of 23% as compared to non-ToF reconstruction. CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Using data from Omni Legend 32 cm, CR and CNR were measured using High Precision DL and QCHD. 5 Precision DL with Omni Legend 32cm improves feature quantitation accuracy by 14% as compared to Discovery MI with ToF reconstruction, at comparable noise level. Quantitation accuracy demonstrated using clinical data with inserted lesions of known size, location, and contrast (ground truth). Feature SUVmean from Omni Legend 32 cm with High Precision DL compared to SUVmean from Discovery MI 25 cm with QCFX. View source version on Contacts GE HealthCare Media Contact Sofia Mata-LeclercHead of Communications, Science and
Business Wire
9 hours ago
- Business Wire
Avnet to Report Fourth Quarter and Fiscal Year 2025 Earnings on August 6 and to Hold Annual Shareholder Meeting on November 21
PHOENIX--(BUSINESS WIRE)-- Avnet (Nasdaq: AVT), a global technology solutions company, today announced it will report financial results for the fourth quarter and fiscal year 2025 on August 6, 2025 before the market opens. Following the earnings release, Avnet's Chief Executive Officer Phil Gallagher and Chief Financial Officer Ken Jacobson will host a webcast and conference call at 9:00 a.m. PT / Noon ET to discuss the financial results and provide a corporate update. Avnet's Board has also scheduled the Annual Meeting of Shareholders for Friday, November 21, 2025 at 8:00 a.m. Phoenix, Arizona time. The meeting will be held at Avnet's Corporate Headquarters located at: 2211 South 47th Street, Phoenix, Arizona 85034. The record date for determining the common shareholders entitled to vote at the meeting has been set at the close of business on September 22, 2025. Earnings Conference Call and Webcast Details To participate in the live call, dial 877-407-8112 or 201-689-8840. The live webcast along with slides can be accessed via Avnet's Investor Relations web page at An audio replay of the webcast will be available after the completion of the call and archived on the Avnet website for one year. About Avnet As a leading global technology distributor and solutions provider, Avnet has served customers' evolving needs for more than a century. Through regional and specialized businesses around the world, we support customers and suppliers at every stage of the product lifecycle. We help companies adapt to change and accelerate the design and supply stages of product development. With a unique viewpoint from the center of the technology value chain, Avnet is a trusted partner that solves complex design and supply chain issues so customers can realize revenue faster. Learn more about Avnet at (AVT_IR)
Hamilton Spectator
a day ago
- Hamilton Spectator
Dark skin was part of his identity until a medical condition stole it away
There was no support for Shahnawaz Towheed when he developed an auto-immune condition that causes the skin to lose its pigment. 'I didn't know anyone else who had my condition, as it only affects about one per cent of the population,' Towheed said. 'There was this sense of feeling alone and not feeling understood either … You sort of hide yourself from certain situations in which people might notice your skin or call it out.' To combat the isolation, the 26-year-old McMaster University medical student created virtual support groups for vitiligo himself — first in the United Kingdom (U.K.) and now in Canada. Finding people who looked like him and who could relate to his story was just as important as medical care for the condition, Towheed said. 'That sense of hopelessness, fear, anxiety and just ultimately not really feeling content with the way you are and the way you look,' Towheed said. 'It took many years, but I was able to allow that to shape me into someone who now has aspirations to support others who are going through the same thing.' Filling that gap in services is so important that Towheed set out to prove the worth of support groups for vitiligo. He was the lead author on a study presented to the Annual Meeting of the British Association of Dermatologists on July 2 in Glasgow. 'I thought it was received in a way that people understood the need,' Towheed said. 'A lot of the presentations there tend to be focused more on medical considerations regarding vitiligo or just things that don't really focus on the emotional or the identity challenges that people can have.' Shahnawaz Towheed as a child before vitiligo took all of his skin pigment. Towheed was six years old when he started to lose dark brown pigment on his left thigh and was diagnosed with vitiligo . His family tried every treatment, but it didn't stop the steady progress of the condition that saw him lose all his pigment by the age of 12. 'I felt a sense of shame and identity loss,' Towheed said. 'Part of my identity was someone who is South Asian and has dark skin and that was something that was gradually taken away.' With nowhere to turn for emotional support in Canada, he eventually teamed up with the Vitiligo Society in the U.K., which supports people living with the condition. He set up a virtual support group in 2023, facilitated the sessions and got feedback from patients on how it was working for the study. 'It became a really good training ground for me to understand how I can apply some of the things that the U.K. group is doing to Canada,' Towheed said. 'A lot of that became the blueprint for what we are doing now.' McMaster University medical student Shahnawaz Towheed created support groups in Canada and the United States so people with vitiligo would not feel so isolated. Towheed co-founded Vitiligo Voices Canada last year to bring support closer to home. It can be found on Instagram at @VitiligoVoicesCanada and on Facebook. 'There's a lot of people out there who may not know about the service and can really benefit,' Towheed said. 'So just making sure that people know they're not alone.' As Towheed is about to enter his last year of medical school this fall, he's considering specializing in psycho dermatology. 'That's actually what my research is really focused on is that mind skin connection,' Towheed said. 'I feel like it's something that I can offer the most to given my connection to it.' Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
